![LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient](https://www.seventure.fr/wp-content/uploads/2016/11/4__104270789-1-322x211.jpg)
1 October 2018
LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient
LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery,has announced the launch of a new clinical trial with Stablor®, OBEMINALE 2,...